Astoria Portfolio Advisors LLC. Has $357,000 Stock Holdings in Danaher Corporation $DHR

Astoria Portfolio Advisors LLC. lessened its holdings in Danaher Corporation (NYSE:DHR) by 3.9% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 1,758 shares of the conglomerate’s stock after selling 72 shares during the quarter. Astoria Portfolio Advisors LLC.’s holdings in Danaher were worth $357,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of DHR. Nuveen LLC acquired a new stake in Danaher during the first quarter valued at $833,941,000. Invesco Ltd. lifted its stake in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Baird Financial Group Inc. lifted its stake in shares of Danaher by 290.6% in the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock valued at $295,550,000 after purchasing an additional 1,072,617 shares during the last quarter. Generation Investment Management LLP raised its holdings in Danaher by 33.2% during the first quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate’s stock valued at $651,515,000 after buying an additional 791,662 shares in the last quarter. Finally, Parnassus Investments LLC raised its holdings in Danaher by 23.3% during the first quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock valued at $784,745,000 after buying an additional 722,636 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Down 1.0%

DHR stock opened at $202.53 on Monday. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.41. The company has a market cap of $145.02 billion, a PE ratio of 43.09, a price-to-earnings-growth ratio of 2.88 and a beta of 0.77. The business’s 50-day simple moving average is $200.66 and its 200 day simple moving average is $197.07. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s payout ratio is presently 27.23%.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 11.10% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on DHR shares. Redburn Partners set a $220.00 target price on Danaher in a report on Wednesday. UBS Group dropped their price objective on Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, July 23rd. Evercore ISI lifted their price objective on Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Barclays reiterated an “overweight” rating and issued a $225.00 price objective (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Finally, Scotiabank upgraded Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price objective on the stock in a research note on Friday, July 11th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $244.60.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.